Abstract:AIMS: The E143K (Glu → Lys) mutation in the myosin essential light chain has been associated with restrictive cardiomyopathy (RCM) in humans, but the mechanisms that underlie the development of defective cardiac function are unknown. Using transgenic E143K-RCM mice, we sought to determine the molecular and cellular triggers of E143K-induced heart remodelling.METHODS AND RESULTS: The E143K-induced abnormalities in cardiac function and morphology observed by echocardiography and invasive haemodynamics were paralleled by augmented active and passive tension measured in skinned papillary muscle fibres compared with wild-type (WT)-generated force. In vitro, E143K-myosin had increased duty ratio and binding affinity to actin compared with WT-myosin, increased actin-activated ATPase activity and slower rates of ATP-dependent dissociation of the acto-myosin complex, indicating an E143K-induced myosin hypercontractility. E143K was also observed to reduce the level of myosin regulatory light chain phosphorylation while that of troponin-I remained unchanged. Small-angle X-ray diffraction data showed a decrease in the filament lattice spacing (d1,0) with no changes in the equatorial reflections intensity ratios (I1,1/I1,0) in E143K vs. WT skinned papillary muscles. The hearts of mutant-mice demonstrated ultrastructural defects and fibrosis that progressively worsened in senescent animals and these changes were hypothesized to contribute to diastolic disturbance and to mild systolic dysfunction. Gene expression profiles of E143K-hearts supported the histopathology results and showed an upregulation of stress-response and collagen genes. Finally, proteomic analysis evidenced RCM-dependent metabolic adaptations and higher energy demands in E143K vs. WT hearts.CONCLUSIONS: As a result of the E143K-induced myosin hypercontractility, the hearts of RCM mice model exhibited cardiac dysfunction, stiff ventricles and physiological, morphologic, and metabolic remodelling consistent with the development of RCM. Future efforts should be directed toward normalization of myosin motor function and the use of myosin-specific therapeutics to avert the hypercontractile state of E143K-myosin and prevent pathological cardiac remodelling.

Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain

Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations

Molecular basis of force-pCa relation in MYL2 cardiomyopathy mice: Role of the super-relaxed state of myosin

Identification and Functional Characterization of KLF5 As a Novel Disease Gene Responsible for Familial Dilated Cardiomyopathy.

The <i>LMNA </i>p.R541C mutation causes dilated cardiomyopathy in human and mice

An alpha-helix variant p.Arg156Pro in LMNA as a cause of hereditary dilated cardiomyopathy: genetics and bioinfomatics exploration

Genetic Mutation of Familial Dilated Cardiomyopathy Based on Next‑generation Semiconductor Sequencing.

A Novel Nkx2-5 Loss-Of-Function Mutation Predisposes to Familial Dilated Cardiomyopathy and Arrhythmias

Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy

Dilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate release

Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice

A Novel GATA4 Loss-of-function Mutation Responsible for Familial Dilated Cardiomyopathy

In vitro rescue study of a malignant familial hypertrophic cardiomyopathy phenotype by pseudo-phosphorylation of myosin regulatory light chain

Detection and functional characterization of a novel <i>MEF2A</i> variation responsible for familial dilated cardiomyopathy

Dilated cardiomyopathy myosin mutants have reduced force-generating capacity

Prevalence and Spectrum of LRRC10 Mutations Associated with Idiopathic Dilated Cardiomyopathy.

Structures of PKA–phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy

MEF2C loss-of-function mutation associated with familial dilated cardiomyopathy.

Clinical and Functional Characterization of a Novel Mutation in Lamin A/C Gene in a Multigenerational Family with Arrhythmogenic Cardiac Laminopathy